calcium signalling

liver
Biotech

CalciMedica stock craters as trial stopped over 'safety concern'

CalciMedica’s stock nosedived after the biotech abandoned a phase 2 study of its calcium release-activated calcium channel inhibitor.
James Waldron Jan 28, 2026 8:40am
winnter trophy star

BridgeBio's calcium deficiency candidate scores phase 3 win

Oct 29, 2025 7:00am
hospital

CalciMedica drug helps some with pancreatitis eat solids sooner

Jun 27, 2024 8:25am